Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.

导出 OA

翻译打印收藏纠错

作者： John W,Baddley ^[1] ; Kevin L,Winthrop ^[2] ; Lang,Chen ^[3] ; Liyan,Liu ^[4] ; Carlos G,Grijalva ^[5] ; Elizabeth,Delzell ^[3] ; Timothy,Beukelman ^[3] ; Nivedita M,Patkar ^[3] ; Fenglong,Xie ^[3] ; Kenneth G,Saag ^[3] ; Lisa J,Herrinton ^[4] ; Daniel H,Solomon ^[6] ; James D,Lewis ^[7] ; Jeffrey R,Curtis ^[3]

作者单位： Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA Medical Service, Birmingham VA Medical Center, Birmingham, Alabama, USA. ^[1] Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA. ^[2] Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA. ^[3] Division of Research, Kaiser Permanente Northern California, Oakland, California, USA. ^[4] Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA. ^[5] Department of Medicine, Boston, Brigham and Women's Hospital-Harvard University, Boston, Massachusetts, USA. ^[6] Center for Clinical Epidemiology and Biostatistics, Perlman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. ^[7]

关键词 DMARDs (biologic)Infections Rheumatoid Arthritis TNF-alpha Tuberculosis